Leucocyte Nadir as a Marker for Chemotherapy Efficacy in Node-Positive Breast Cancer Treated With Adjuvant CMF

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6690594
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides

JAMA Dermatology
DermatologyMedicine
2016English

Randomised Trial: Survival Benefit and Safety of Adjuvant Dose-Dense Chemotherapy for Node-Positive Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Subclinical Cardiotoxicity Following Adjuvant Dose-Escalated FEC, High-Dose Chemotherapy, or CMF in Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2000English

Adjuvant Chemotherapy Versus Observation After Radical Cystectomy in Patients With Node-Positive Bladder Cancer

Scientific Reports
Multidisciplinary
2019English

Adjuvant Chemotherapy for Early Breast Cancer.

BMJ
1983English

CAF vs. CMF Combination Chemotherapy in Advanced Breast Cancer Patients

International Journal of Science and Research (IJSR)
2016English

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Adjuvant Chemotherapy for Node Negative, High Recurrence ScoreTM Breast Cancer: In Defense of De-Escalation

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy